This may be the case - from a business point of view, if they think COVID will work ( and they obviously do ), then the company effort would be better spent setting up 10,000 doses per 6 months, than trying to run yet another GVHD trial to treat 1000 patients at most per year.
In the current circumstance it makes more sense for Doctors to use it off label for GvHD, following positive COVID approval which will happen before any further GvHD trial completes.
MSB Price at posting:
$3.27 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)